Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Zealand Pharma Aktieselskabet : reports Q1 2017 royalty revenue

share with twitter share with LinkedIn share with facebook
share via e-mail
04/29/2017 | 02:18pm CEST

(GlobeNewswire) - Company announcement - No. 13/2017

Zealand reports Q1 2017 royalty revenue

Zealand reports royalty revenue of DKK 8.0 million in Q1 2017

DKK 5.1 million arises from royalties on sales of Lyxumia/Adlyxin(TM)

DKK 2.9 million arises from royalties on the first sales of Soliqua 100/33 in the U.S.

Copenhagen, April 28, 2017 - Zealand Pharma ("Zealand") reports Q1 2017 royalty revenue from Sanofi`s sales of Lyxumia/Adlyxin(TM) (lixisenatide) of DKK 5.1 million and from Soliqua 100/33 of DKK 2.9 million.

Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand. Zealand licensed the global development and commercialization rights to lixisenatide to Sanofi. Lixisenatide is marketed under the brand name Lyxumia in over 45 countries and was launched in the United States under the brand name Adlyxin(TM) in January 2017.

Sanofi has also developed a combination of lixisenatide and insulin glargine 100 units/mL (Lantus), which was launched under the brand name Soliqua100/33 in the United States in January 2017 and is expected to launch under the brand name Suliqua in certain EU countries starting from the second quarter of 2017.

Since January 2017, Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) has been available by prescription in US pharmacies. Soliqua 100/33 is approved in the United States as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide alone.

Zealand`s Interim report for the first three months of 2017 will be published on May 17 and will contain more information relating to the launch of Soliqua 100/33.

For further information, please contact:

Britt Meelby Jensen, CEO and President Tel.: +45 51 67 61 28, e-mail: [email protected]

Mats Blom, Senior Vice President, Chief Financial OfficerTel.: +45 31 53 79 73, e-mail: [email protected]

About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases.2Zealand`s first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin in the U.S. and as Lyxumia in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus) and is marketed as Soliqua 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe.

Zealand`s pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company`s business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).



(c) 2017 Daily News Egypt. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
04/29 ZEALAND PHARMA AKTIESELSKABET : reports Q1 2017 royalty revenue
04/29 SANOFI : Evidation Health Secures Financing From Sanofi-Genzyme BioVentures to F..
04/28 SANOFI SA (NYSE : SNY) reported earnings of $1.42 per share beating Walls Street..
04/28 SANOFI : beats 1Q profit forecasts
04/28 SANOFI : and Regeneron receive CHMP positive opinion for rheumatoid arthritis tr..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/28 SANOFI : Delivers Robust Q1 2017 Financial Results
04/28 SANOFI : and Regeneron Announce Kevzara® (sarilumab) Biologics License Applicati..
04/28 SANOFI : Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Ap..
More news
Sector news : Pharmaceuticals - NEC
03:15pDJPFIZER : Drug Makers Take Page From Hollywood to Spread the Risk
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 SNIPPETS ROUNDUP : Sanofi Diabetes Disappointment, And Amgen Pullback Signals CG..
04/28 Sanofi SA (SNY) CEO Olivier Brandicourt on Q1 2017 Results - Earnings Call Tr..
04/28 Sanofi 2017 Q1 - Results - Earnings Call Slides
04/28 FDA accepts sarilumab BLA resubmission, action date May 22
04/28 Sanofi Q1 top line up 11%; earnings up 425% on sale of animal heath unit; sha..
Financials (€)
Sales 2017 36 455 M
EBIT 2017 9 316 M
Net income 2017 6 663 M
Debt 2017 4 680 M
Yield 2017 3,51%
P/E ratio 2017 16,71
P/E ratio 2018 17,91
EV / Sales 2017 3,20x
EV / Sales 2018 3,06x
Capitalization 111 902 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 83,5 €
Spread / Average Target -3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI12.63%121 897
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.31%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results